A comparison of postprocedural anticoagulation in high ‐risk patients undergoing WATCHMAN device implantation

ConclusionFor patients with AF at high risk of both thromboembolic and hemorrhagic events, NOACs as compared to Warfarin, seem to be safe and effective for short ‐term anticoagulation following LAAC with the WATCHMAN device. Further validation in large randomized controlled trials is required.

Source: Pacing and Clinical Electrophysiology : PACE - September 16, 2019 Category: Cardiology Authors: Joshua A. Cohen, E. Kevin Heist, Jennifer Galvin, Hang Lee, Matthew Johnson, Michael Fitzsimons, Kathryn Slattery, Brian Ghoshhajra, Rahul Sakhuja, Grace Ha, Margaux Forsch, Linsheng Shi, Jacqueline Danik, Jacob Dal ‐Bianco, Danita Sanborn Tags: ELECTROPHYSIOLOGY Source Type: research